Antigen Disclosures Sample Clauses

Antigen Disclosures. Except as provided in this Section 6.5.1(b), Medarex covenants to Kirin and Kirin covenants to Medarex that during the Term neither it nor any of its Affiliates will enter into a Project Agreement governing a Partner Project, which Project Agreement provides for the grant by such Party to a Partner of a sublicense under a Reservation License or a Commercial License with respect to Antibodies raised against and with affinity for a particular Antigen, and/or Antibody Products containing such Antibodies, in each case in connection with such Partner Project, unless the terms and conditions of such Project Agreement permit such Party to notify the other Party of the identity of any such Antigen and the identity of the Partner within [*] days after the earlier of (i) the grant by the contracting Party to the Partner of a sublicense under a Commercial License with respect to such Antigen in connection with such Partner Project, or (ii) public disclosure of the fact that a particular Antibody (or Antibody Product) was developed by the Partner in connection with such Partner Project through use of the non-contracting Party's mice or Technology and/or the KM-Mice or KM Patent Rights, as the case may be. For the avoidance of doubt, if a Third Party will not agree to permit a Party to include in the Project Agreement, terms that satisfy the requirements of Sections 6.5.1(a) and 6.5.1(b), such Party (or its Affiliate) may not enter into the Project Agreement with such Third Party governing a Partner Project; provided, however, that in the case of [*] (or a [*] Affiliate, as permitted under Section 8.5.3 to the extent applicable) as the contracting Party, [*] or its Affiliate [*] a [*] governing a [*] or [*] with a Third Party which [*] after [*] to have [*], but [*], in that or any other agreement or legally binding understanding, [*] such Third Party [*] or other [*] the [*] unless the Third Party [*]. Notwithstanding the foregoing, in the event that Medarex, after [*], is [*] the agreement of a Third Party to [*] such [*] to [*] in accordance with this Section 6.5.1(b), it shall not be deemed a [*] to [*] to [*] such [*] and Kirin shall [*] to [*] or otherwise bring [*] for [*] to [*] the Third Party the [*] such [*] or for [*] a [*] governing a [*] or [*] with the Third Party [*] such [*] to the [*] of such [*]; provided, [*]=Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and...
AutoNDA by SimpleDocs
Antigen Disclosures. During the Term of this Agreement, if a Party desires to know the [*] of an [*] for which a particular [*] has [*] a [*] a [*] or a [*] with respect to [*], and/or [*], in each case in connection with such Partner Project, such Party shall provide written notice thereof to the other Party within [*] days after the receipt of such notice from the other Party disclosing the identity of such Partner pursuant to Section 6.5.2(a) hereof. From and after the receipt of such notice from the non-contracting Party, the contracting Party shall notify the non-contracting Party of the identity of any such Antigen and the identity of such Partner within [*] days after the earlier of (i) the grant by the contracting Party to the Partner of a sublicense under a Commercial License with respect to such Antigen in connection with such Partner Project, or (ii) public disclosure of the fact that a particular Antibody (or Antibody Product) was developed by the Partner in connection with such Partner Project through use of the non-contracting Party's mice or Technology and/or KM-Mice or KM Patent Rights, as the case may be. Notwithstanding the foregoing, in the event that Medarex, [*] is [*] the agreement of a Third Party [*] in accordance with this Section 6.5.2(b), it shall not be deemed a [*] to [*] to [*] such [*] and Kirin shall [*] or otherwise bring [*] for [*] or [*] to [*] the Third Party the [*] such [*] or for [*] a [*] governing a [*] or [*] with the Third Party [*] such [*] to the [*] of such [*]; provided, however, that nothing herein is intended to limit [*], if any, or [*], if any, with respect to the [*] of any other [*] or [*] in this Agreement, including without limitation, [*] a [*] or other [*] the [*] to a Third Party which [*]. For the avoidance of doubt, for purposes of this Section 6.5.2(b), [*] shall [*] to [*] to the Third Party in the [*] of such [*]

Related to Antigen Disclosures

  • Information Disclosure Each Party shall, and shall cause its Affiliates, licensees and sublicensees, as applicable, to, without additional compensation and at such Party's sole expense, disclose and make available to the other Party, in whatever form each such other Party may reasonably request, all Regulatory Documentation, all of its other Know-How, all Information and Inventions included in the Collaboration Technology and any other Information and Inventions relating, directly or indirectly, to the Exploitation of any Collaboration Products immediately after the Effective Date and thereafter immediately upon the earlier of the conception or reduction to practice, discovery, development or making of each such Regulatory Documentation, Know-How, or other Information and Inventions.

  • Certain Disclosures A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of 1) the structure of the Blue Cross and Blue Shield System; and 2) the independent nature of every licensee; and 3) the Controlled Affiliate's financial condition.

  • Invention Disclosure Invention Disclosure" means a disclosure of an invention (i) written for the purpose of allowing legal and business people to determine whether to file a Patent application with respect to such invention and (ii) recorded with a control number in the owning party's records.

  • Confidential Information and Inventions (a) The Executive recognizes and acknowledges that in the course of his duties he is likely to receive confidential or proprietary information owned by the Company, its affiliates or third parties with whom the Company or any such affiliates has an obligation of confidentiality. Accordingly, during and after the Term, the Executive agrees to keep confidential and not disclose or make accessible to any other person or use for any other purpose other than in connection with the fulfillment of his duties under this Agreement, any Confidential and Proprietary Information (as defined below) owned by, or received by or on behalf of, the Company or any of its affiliates. “Confidential and Proprietary Information” shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data, formulas and related concepts, business plans (both current and under development), client lists, promotion and marketing programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs, revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, financing methods, plans or the business and affairs of the Company or of any affiliate or client of the Company. The Executive expressly acknowledges the trade secret status of the Confidential and Proprietary Information and that the Confidential and Proprietary Information constitutes a protectable business interest of the Company. The Executive agrees: (i) not to use any such Confidential and Proprietary Information for himself or others; and (ii) not to take any Company material or reproductions (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof from the Company’s offices at any time during his employment by the Company, except as required in the execution of the Executive’s duties to the Company. The Executive agrees to return immediately all Company material and reproductions (including but not limited, to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof in his possession to the Company upon request and in any event immediately upon termination of employment.

  • Disclosure Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

  • Confidential Information; Non-Disclosure In consideration of your access to certain Confidential Information (as defined below) of the Company, in connection with your business relationship with the Company, you hereby represent and agree as follows:

  • Confidential Information and Non-Disclosure Employee acknowledges and agrees that Employee’s employment by the Company necessarily involves Employee’s knowledge of and access to confidential and proprietary information pertaining to the business of the Company. Accordingly, Employee agrees that at all times during the term of this Agreement and for as long as the information remains confidential after the termination of Employee's employment, Employee will not, directly or indirectly, without the express written authority of the Company, unless directed by applicable legal authority having jurisdiction over Employee, disclose to or use, or knowingly permit to be so disclosed or used, for the benefit of Employee, any person, corporation or other entity other than the Company, (i) any information concerning any financial matters, employees of the Company, customer relationships, competitive status, supplier matters, internal organizational matters, current or future plans, or other business affairs of or relating to the Company, (ii) any management, operational, trade, technical or other secrets or any other proprietary information or other data of the Company, or (iii) any other information related to the Company which has not been published and is not generally known outside of the Company. Employee acknowledges that all of the foregoing constitutes confidential and proprietary information, which is the exclusive property of the Company. Nothing in this Section 16 prohibits Employee from reporting possible violations of federal, state, or local law or regulation to any governmental agency or entity, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation.

  • ADV Disclosure The Adviser has provided the Trust with a copy of its Form ADV as most recently filed with the Commission and will, promptly after filing any amendment to its Form ADV with the Commission, furnish a copy of such amendments to the Trust. The information contained in the Adviser’s Form ADV is accurate and complete in all material respects and does not omit to state any material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading.

  • Confidential Information and Intellectual Property (a) Other than in the performance of the Executive’s duties hereunder, the Executive agrees not to use in any manner or disclose, distribute, publish, communicate or in any way cause to be used, disclosed, distributed, published, or communicated in any way or at any time, either while in the Company's employ or at any time thereafter, to any person not employed by the Company, or not engaged to render services to the Company, any Confidential Information (as defined below) obtained while in the employ of the Company.

  • Non-Disclosure of Third Party Information Executive represents and warrants and covenants that Executive shall not disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others at any time, including but not limited to any proprietary information or trade secrets of any former employer, if any; and Executive acknowledges and agrees that any violation of this provision shall be grounds for Executive’s immediate termination and could subject Executive to substantial civil liabilities and criminal penalties. Executive further specifically and expressly acknowledges that no officer or other employee or representative of the Company has requested or instructed Executive to disclose or use any such third party proprietary information or trade secrets.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!